These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 27477200)

  • 1. Problems with traffic ahead: Synaptic vesicles in Parkinson's disease.
    Pifl C
    Mov Disord; 2016 Oct; 31(10):1480. PubMed ID: 27477200
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein.
    Lotharius J; Brundin P
    Nat Rev Neurosci; 2002 Dec; 3(12):932-42. PubMed ID: 12461550
    [No Abstract]   [Full Text] [Related]  

  • 3. Parkinson's disease. Dopamine may sustain toxic protein.
    Couzin J
    Science; 2001 Nov; 294(5545):1257-8. PubMed ID: 11701896
    [No Abstract]   [Full Text] [Related]  

  • 4. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interactions between cell adhesion and the synaptic vesicle cycle in Parkinson's disease.
    Chapman MA
    Med Hypotheses; 2014 Aug; 83(2):203-7. PubMed ID: 24837686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias.
    de la Fuente-Fernández R; Sossi V; Huang Z; Furtado S; Lu JQ; Calne DB; Ruth TJ; Stoessl AJ
    Brain; 2004 Dec; 127(Pt 12):2747-54. PubMed ID: 15329355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synaptic plasticity, dopamine and Parkinson's disease: one step ahead.
    Calabresi P; Mercuri NB; Di Filippo M
    Brain; 2009 Feb; 132(Pt 2):285-7. PubMed ID: 19168452
    [No Abstract]   [Full Text] [Related]  

  • 8. Synaptic vesicle trafficking and Parkinson's disease.
    Esposito G; Ana Clara F; Verstreken P
    Dev Neurobiol; 2012 Jan; 72(1):134-44. PubMed ID: 21563316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease.
    Nandhagopal R; Kuramoto L; Schulzer M; Mak E; Cragg J; McKenzie J; McCormick S; Ruth TJ; Sossi V; de la Fuente-Fernandez R; Stoessl AJ
    Brain; 2011 Nov; 134(Pt 11):3290-8. PubMed ID: 22075521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?
    Sidhu A; Wersinger C; Vernier P
    FASEB J; 2004 Apr; 18(6):637-47. PubMed ID: 15054086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A convergent model for cognitive dysfunctions in Parkinson's disease: the critical dopamine-acetylcholine synaptic balance.
    Calabresi P; Picconi B; Parnetti L; Di Filippo M
    Lancet Neurol; 2006 Nov; 5(11):974-83. PubMed ID: 17052664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study.
    Sossi V; de la Fuente-Fernández R; Schulzer M; Troiano AR; Ruth TJ; Stoessl AJ
    Ann Neurol; 2007 Nov; 62(5):468-74. PubMed ID: 17886297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine neurotransmission and treatments for Parkinson's disease in the molecular biology era.
    Ogawa N
    Eur Neurol; 1997; 38 Suppl 1():2-5. PubMed ID: 9276193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness?
    Wienecke M; Werth E; Poryazova R; Baumann-Vogel H; Bassetti CL; Weller M; Waldvogel D; Storch A; Baumann CR
    J Sleep Res; 2012 Dec; 21(6):710-7. PubMed ID: 22747735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective and toxic roles of dopamine in Parkinson's disease.
    Segura-Aguilar J; Paris I; Muñoz P; Ferrari E; Zecca L; Zucca FA
    J Neurochem; 2014 Jun; 129(6):898-915. PubMed ID: 24548101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ; Jenner P
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease.
    Kumar A; Mann S; Sossi V; Ruth TJ; Stoessl AJ; Schulzer M; Lee CS
    Brain; 2003 Dec; 126(Pt 12):2648-55. PubMed ID: 12937076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysfunction of dopamine homeostasis: clues in the hunt for novel Parkinson's disease therapies.
    Bisaglia M; Greggio E; Beltramini M; Bubacco L
    FASEB J; 2013 Jun; 27(6):2101-10. PubMed ID: 23463698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.
    Prescott IA; Dostrovsky JO; Moro E; Hodaie M; Lozano AM; Hutchison WD
    Brain; 2009 Feb; 132(Pt 2):309-18. PubMed ID: 19050033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.